title: Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection.
authors.affiliation: Renal Division, Department of Internal Medicine, Washington University in St. Louis, St. Louis, MO.|Transplant Epidemiology Research Collaboration (TERC), Institute of Public Health, Washington University in St. Louis, St. Louis, MO.
authors.forename: T
authors.initials: T
authors.lastname: Alhamad
authors.affiliation: Renal Division, Department of Internal Medicine, Washington University in St. Louis, St. Louis, MO.
authors.forename: K
authors.initials: K
authors.lastname: Venkatachalam
authors.affiliation: Division of Oncology, Department of Internal Medicine, Washington University in St. Louis, St. Louis, MO.
authors.forename: G P
authors.initials: GP
authors.lastname: Linette
authors.affiliation: Renal Division, Department of Internal Medicine, Washington University in St. Louis, St. Louis, MO.
authors.forename: D C
authors.initials: DC
authors.lastname: Brennan
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors*; D006084:Graft Rejection / Q000209:etiology*; D006085:Graft Survival; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000601:surgery*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000209:etiology / Q000556:secondary; D011183:Postoperative Complications; D011379:Prognosis; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*; D012307:Risk Factors; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D066027:Transplant Recipients
chemical_list: D000970:Antineoplastic Agents; D060908:CTLA-4 Antigen; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor